Unconjugated NSS-01
The lead preclinical candidate, with pancreatic and colorectal cancer as primary development priorities, supported by in vivo research and cell-based studies in additional solid tumors.
The next stage
starts with a partner.
We welcome discussions about licensing, acquisition of the NSS-01 program, or co-development, with pancreatic and colorectal cancer as co-equal development priorities.
The product opportunity spans standalone drug development, evaluation as a potential replacement for irinotecan or topotecan in selected combinations, and exploration as an alternative topoisomerase I ADC payload.
Licensing
License the NSS-01 program.
Program sale
Acquire the NSS-01 program.
Co-development
Develop the program together.
THE TRANSACTION OPPORTUNITYThe program
The program
and its assets.
Licensing, sale of the NSS-01 program, and co-development are open transaction options. We welcome discussions about the structure that best supports the program’s next stage.
Proprietary synthesis & formulations
The proposed transaction includes synthesis and formulation development associated with the program.
Exploratory conjugated forms
Additional targeted-delivery research offers an exploratory development direction, separate from the unconjugated candidate’s efficacy evidence.
DEVELOPMENT OPPORTUNITIESOne molecule.
One molecule.
Three development paths.
Pancreatic and colorectal cancer are co-equal priorities for NSS-01. Research in the presence of human serum albumin (HSA) is central to the program’s scientific rationale. The opportunity spans development of the drug itself, its potential role within combination regimens and its evaluation as a topoisomerase I ADC payload.
Standalone drug candidate
Advance unconjugated NSS-01 as a single-agent oncology candidate and evaluate its potential as an alternative to irinotecan or topotecan. Pancreatic and colorectal preclinical findings provide the research foundation.
Potential combination replacement
Evaluate whether NSS-01 could replace the camptothecin-derived component of selected combination regimens, including approaches that use irinotecan or topotecan.
Alternative ADC payload
Evaluate NSS-01 as an alternative topoisomerase I payload for ADC programs that use this drug class, with suitability assessed for each antibody–linker–payload design.
The efficacy findings presented here concern unconjugated NSS-01.
A USEFUL FIRST CONVERSATIONFrom initial interest
From initial interest
to scientific evaluation.
Review the nonconfidential overview
Understand the candidate, the comparative findings and the current development priorities.
Download PowerPoint overview ↓Discuss strategic fit
Talk through your pancreatic and colorectal oncology priorities, development capabilities and interest in the program.
Scope further diligence
Discuss access to study protocols, group sizes, raw data, synthesis information and the IP package as appropriate.
DIRECT PARTNERING CONTACTLet’s discuss
Let’s discuss
NSS-01.
For licensing, sale of the NSS-01 program, or co-development inquiries, contact Bryce directly.
OUR LITTLE ROCK OFFICENatural State Science, LLC
415 North McKinley Street, Suite 770
Little Rock, Arkansas 72205
415 North McKinley Street, Suite 770
Little Rock, Arkansas 72205
Bryce WarrenCo-Founder / Natural State Sciencebwarren@naturalstatescience.com 501 454 0102
Your email app will open with an editable draft.